AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17166443 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 86
Study 15317602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (90 mg)
Number of subjects: 15
Study 15317602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11514302 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 12
Study 11514302 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 9431633 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise treatment program involving training of deep abdominal muscles and co-activation of lumbar multifidus for 10 weeks
Number of subjects: 44
Study 9431633 — intervention group
Group type: COMPARATOR
Intervention: Control treatment as directed by treating practitioner
Number of subjects: 44
Study 8487344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 592
Study 8487344 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 592
Study 8487344 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (specifically for patients with colon injuries)
Number of subjects: 592
Study 3388875 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate (4 g/day)
Number of subjects: 120
Study 3388875 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidinhydrochloride (336 mg/day)
Number of subjects: 120
Study 3388875 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidinhydrochloride and pirenzepindihydrochloride (100 mg/day)
Number of subjects: 120
Study 3388875 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 120
Study 31177181 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual daily physical activity (measured by total physical activity counts - TAC)
Number of subjects: 230
Study 28368179 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT + SCT
Number of subjects: 111
Study 28368179 — intervention group
Group type: COMPARATOR
Intervention: TCT-only
Number of subjects: 111
Study 26299226 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day mortality/HF rehospitalization
Number of subjects: 7141
Study 26299226 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day mortality/all-cause rehospitalization
Number of subjects: 7141
Study 26299226 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day all-cause mortality
Number of subjects: 7141
Study 26299226 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model for 180-day all-cause mortality
Number of subjects: 7141
Study 26299226 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified risk score including age, systolic blood pressure, sodium, blood urea nitrogen, and dyspnea at rest
Number of subjects: 7141
Study 23835511 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 157
Study 23835511 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 157
Study 20440633 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogenic graft (Gent‐Tech)
Number of subjects: 22
Study 20440633 — intervention group
Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 22
Study 18564231 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0
Study 18564231 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0
Study 18564231 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine-ER 4 mg
Number of subjects: 0
Study 18564231 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 16476160 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression assessment
Number of subjects: 681
Study 16476160 — intervention group
Group type: COMPARATOR
Intervention: Follow-up survey
Number of subjects: 681
Study 15331567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trientine therapy for 7 weeks in diabetic rats
Number of subjects: 0
Study 15331567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trientine treatment for 6 months in humans with type 2 diabetes
Number of subjects: 0
Study 15331567 — intervention group
Group type: COMPARATOR
Intervention: Administration of Cu-selective transition metal chelator trientine
Number of subjects: 0
Study 10819335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (twice weekly for 6 months) with isoniazid 15 mg/kg/dose, rifampin 15 mg/kg/dose, and pyrazinamide 55 mg/kg/dose for 2 months, followed by isoniazid and rifampin only for 4 months.
Number of subjects: 206
Study 10819335 — intervention group
Group type: COMPARATOR
Intervention: Daily treatment (weekday) with isoniazid 10 mg/kg/day, rifampin 10 mg/kg/day, and pyrazinamide 25 mg/kg/day for 6 months.
Number of subjects: 206
Study 8531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents and siblings of patients with adenomas
Number of subjects: 1031
Study 8531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of patients diagnosed with adenomas before 60 years of age
Number of subjects: 1031
Study 8531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of patients with a parent who had colorectal cancer
Number of subjects: 1031
Study 1996926 — intervention group
Group type: EXPERIMENTAL
Intervention: PSL‐LBNP tests (4 tests, same protocol, separated by at least 72 h)
Number of subjects: 20
Study 1996926 — intervention group
Group type: EXPERIMENTAL
Intervention: PSL‐LBNP tests with varying stage durations (1-, 3-, 5-, 7-, or 9-min)
Number of subjects: 20
Study 6352280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) 75 mg/m2, administered i.v. bolus every 3 weeks
Number of subjects: 83
Study 6352280 — intervention group
Group type: COMPARATOR
Intervention: Carminomycin (CMM) 20 mg/m2, administered i.v. bolus every 3 weeks
Number of subjects: 83
Study 31146774 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at nine acupuncture points (GV20, EX-HN1, bilateral LI4, and ST36) twice a week for 12 weeks
Number of subjects: 50
Study 31146774 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment at the same points with non-penetrating sham needles
Number of subjects: 50
Study 28748371 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated resistance exercise (HOT30 °C)
Number of subjects: 16
Study 28748371 — intervention group
Group type: COMPARATOR
Intervention: Temperate resistance exercise (CON20 °C)
Number of subjects: 16
Study 26293925 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week tailored home exercise programme
Number of subjects: 70
Study 26293925 — intervention group
Group type: COMPARATOR
Intervention: Advice about exercise and usual care
Number of subjects: 70
Study 23384119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0
Study 23384119 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 21375669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 µg
Number of subjects: 100
Study 21375669 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin 20 units
Number of subjects: 100
Study 19075271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab (2 mg infused over 20 minutes at weeks 0, 4, and 8, then every 12 weeks until recurrence or up to year 5)
Number of subjects: 373
Study 19075271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infused over 20 minutes at weeks 0, 4, and 8, then every 12 weeks until recurrence or up to year 5)
Number of subjects: 373
Study 19075271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab
Number of subjects: 373
Study 19075271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 17848834 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI+rhTSH (0.45 mg of rhTSH prior to treatment)
Number of subjects: 14
Study 17848834 — intervention group
Group type: COMPARATOR
Intervention: RAI (no rhTSH pre-treatment)
Number of subjects: 14
Study 15377348 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT treatment
Number of subjects: 10
Study 15377348 — intervention group
Group type: COMPARATOR
Intervention: Light alone
Number of subjects: 10
Study 15377348 — intervention group
Group type: COMPARATOR
Intervention: ALA alone
Number of subjects: 10
Study 15377348 — intervention group
Group type: COMPARATOR
Intervention: Untreated control site
Number of subjects: 10
Study 11855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day + Vitamin E 600 IU/day (G5)
Number of subjects: 140
Study 11855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 600 IU/day (G2)
Number of subjects: 140
Study 11855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (G4)
Number of subjects: 140
Study 11855664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (G1, G3)
Number of subjects: 140
Study 11855664 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 140
Study 9751554 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-the-boot ankle braces
Number of subjects: 777
Study 9751554 — intervention group
Group type: COMPARATOR
Intervention: Non-brace wearers
Number of subjects: 777
Study 9751554 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace wearers
Number of subjects: 777
Study 7818590 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin treatment
Number of subjects: 0
Study 2907315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0
Study 2907315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0
Study 2907315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 0
Study 2907315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30458684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter-directed thrombolysis
Number of subjects: 60
Study 30458684 — intervention group
Group type: COMPARATOR
Intervention: Non-guided catheter-directed thrombolysis
Number of subjects: 60
Study 26350110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/100 Hz TEAS
Number of subjects: 80
Study 26350110 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 80
Study 26350110 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 25432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily emtricitabine/tenofovir
Number of subjects: 0
Study 25432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent emtricitabine/tenofovir
Number of subjects: 0
Study 25432877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25432877 — intervention group
Group type: COMPARATOR
Intervention: Intermittent placebo
Number of subjects: 0
Study 24377213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and moxibustion
Number of subjects: 160
Study 24377213 — intervention group
Group type: COMPARATOR
Intervention: Western medication (glucosamine sulfate capsules and joint cavity injections)
Number of subjects: 160
Study 20807278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU group, n = 17)
Number of subjects: 80
Study 20807278 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (ACU-sham group, n = 13)
Number of subjects: 80
Study 20807278 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 80
Study 20807278 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (AMIO reference group, n = 26)
Number of subjects: 80
Study 19427632 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity between the pACC and amygdala in BD group
Number of subjects: 33
Study 16968802 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 microg/kg)
Number of subjects: 13
Study 16968802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 13
Study 14557011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclogest vaginal suppositories 400mg twice daily
Number of subjects: 60
Study 14557011 — intervention group
Group type: COMPARATOR
Intervention: Crinone 8% vaginal gel once daily
Number of subjects: 60
Study 10798738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 78
Study 10798738 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 78
Study 8824669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with thawed frozen donor semen, prepared by double wash and swim-up
Number of subjects: 54
Study 8824669 — intervention group
Group type: COMPARATOR
Intervention: Pericervical insemination with unprepared thawed frozen donor semen
Number of subjects: 54
Study 1730487 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 906 (ISP1820 delta aroC delta aroD)
Number of subjects: 36
Study 1730487 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908 (Ty2 delta aroC delta aroD)
Number of subjects: 36
Study 1730487 — intervention group
Group type: EXPERIMENTAL
Intervention: chi 3927 (Ty2 delta cya delta crp)
Number of subjects: 36
Study 1730487 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 906, CVD 908, chi 3927
Number of subjects: 36
Study 6702562 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 16
Study 6702562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30564971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-led intervention to improve medication adherence
Number of subjects: 17
Study 30564971 — intervention group
Group type: EXPERIMENTAL
Intervention: Morisky Scale
Number of subjects: 17
Study 30564971 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief About Medicines Questionnaire-Specific
Number of subjects: 17
Study 30361766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 8
Study 30361766 — intervention group
Group type: COMPARATOR
Intervention: Sham-IPC
Number of subjects: 8
Study 27053383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral- and vitamin-enhanced micronutrient powder (MNP)
Number of subjects: 467
Study 27053383 — intervention group
Group type: COMPARATOR
Intervention: Water-based hand sanitizer (HS)
Number of subjects: 467
Study 27053383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HS and MNP
Number of subjects: 467
Study 27053383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HS and no MNP)
Number of subjects: 467
Study 25084682 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in primary care provider (PCP)
Number of subjects: 701
Study 25084682 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in doctors in general
Number of subjects: 701
Study 22182418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego depletion manipulation
Number of subjects: 80
Study 22182418 — intervention group
Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 80
Study 19597520 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training (up to 1 hour, three times a week for 6 weeks)
Number of subjects: 30
Study 19597520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training or additional therapy)
Number of subjects: 30
Study 18455656 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (50 g daily)
Number of subjects: 100
Study 18455656 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (3 g in 500 mL of water daily)
Number of subjects: 100
Study 18455656 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (50 g daily) and Green tea (3 g daily)
Number of subjects: 100
Study 18455656 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypocholesterolemic diet)
Number of subjects: 100
Study 16189968 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed integrated method for classifier fine-tuning and kinematic variable selection
Number of subjects: 0
Study 16189968 — intervention group
Group type: COMPARATOR
Intervention: Bayesian classifiers with dimensionality reduction techniques
Number of subjects: 0
Study 14509156 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC1
Number of subjects: 40
Study 14509156 — intervention group
Group type: EXPERIMENTAL
Intervention: Met‐HGF/SF
Number of subjects: 40
Study 14509156 — intervention group
Group type: COMPARATOR
Intervention: Control group (malignant melanoma patients)
Number of subjects: 40
Study 9505134 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex stimuli during habituation training
Number of subjects: 70
Study 9505134 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse-reflex stimulus pairings during habituation training
Number of subjects: 70
Study 9505134 — intervention group
Group type: EXPERIMENTAL
Intervention: Random sequence of prepulse and reflex stimuli during habituation training
Number of subjects: 70
Study 9505134 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse stimuli during habituation training
Number of subjects: 70
Study 9505134 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally irrelevant light stimuli during habituation training
Number of subjects: 70
Study 7785574 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 21
Study 7785574 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroanterior and lateral radiographs (21 measurements)
Number of subjects: 21
Study 7785574 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroanterior radiograph (2 measurements)
Number of subjects: 21
Study 2356907 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses of White male physicians regarding breaching confidentiality for HIV-infected patients.
Number of subjects: 199
Study 2356907 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses of White male physicians regarding informing the patient's partner.
Number of subjects: 199
Study 354615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous droperidol (Inapsine)
Number of subjects: 165
Study 354615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 165
Study 30573159 — intervention group
Group type: EXPERIMENTAL
Intervention: Annurca apple polyphenolic extract (AMS), 4 capsules/day for 24 weeks
Number of subjects: 180
Study 30573159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin capsules)
Number of subjects: 180
Study 28952891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term storage group (freshest available red cells, mean storage duration 11.8 days)
Number of subjects: 4994
Study 28952891 — intervention group
Group type: COMPARATOR
Intervention: Long-term storage group (standard-issue red cells, mean storage duration 22.4 days)
Number of subjects: 4994
Study 28952891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term storage group
Number of subjects: 4994
Study 28952891 — intervention group
Group type: COMPARATOR
Intervention: Long-term storage group
Number of subjects: 4994
Study 26655129 — intervention group
Group type: COMPARATOR
Intervention: OAC-1 group (1 week treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Number of subjects: 298
Study 26655129 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-2 group (2 weeks treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Number of subjects: 298
Study 26655129 — intervention group
Group type: COMPARATOR
Intervention: OAC-1 group (1 week treatment)
Number of subjects: 298
Study 26655129 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-2 group (2 weeks treatment)
Number of subjects: 298
Study 23086558 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 58
Study 23086558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 21996279 — intervention group
Group type: EXPERIMENTAL
Intervention: Quicktrach™ kit
Number of subjects: 20
Study 21996279 — intervention group
Group type: COMPARATOR
Intervention: Melker™ kit
Number of subjects: 20
Study 21996279 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Quicktrach™ and Melker™ kits
Number of subjects: 20
Study 21996279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference indicated by residents
Number of subjects: 20
Study 18076644 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (n=23)
Number of subjects: 41
Study 18076644 — intervention group
Group type: COMPARATOR
Intervention: Conventional (n=18)
Number of subjects: 41
Study 16513521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing adjusted for the source‐to‐target distance (DA group)
Number of subjects: 48
Study 16513521 — intervention group
Group type: COMPARATOR
Intervention: Recommended dose prescription protocol (S group)
Number of subjects: 48
Study 12602655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication; effectiveness assessed through factor analysis; specific dosage and duration not mentioned.
Number of subjects: 0
Study 11493096 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐B 311‐nm phototherapy alone (group B)
Number of subjects: 71
Study 11493096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of saline spa water and UV‐B therapy (group C)
Number of subjects: 71
Study 11493096 — intervention group
Group type: COMPARATOR
Intervention: Saline spa water alone (group A)
Number of subjects: 71
Study 11493096 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study 9612329 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg over 10 min) during high sodium intake (250 mmol/day)
Number of subjects: 12
Study 9612329 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg over 10 min) during low sodium intake (77 mmol/day)
Number of subjects: 12
Study 8296408 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin albumin-solution
Number of subjects: 22
Study 8296408 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin lyophilisate
Number of subjects: 22
Study 3191000 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil
Number of subjects: 35
Study 3191000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7984241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisdioxopiperazines (topoisomerase II inhibitors) such as ICRF-193
Number of subjects: 0
Study 7984241 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (checkpoint-evading agent)
Number of subjects: 0